DURECT Corp
NASDAQ:DRRX

Watchlist Manager
DURECT Corp Logo
DURECT Corp
NASDAQ:DRRX
Watchlist
Price: 1.91 USD -1.04% Market Closed
Market Cap: 59.3m USD

Net Margin
DURECT Corp

-111.5%
Current
-288%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-111.5%
=
Net Income
-3.5m
/
Revenue
3.1m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
DURECT Corp
NASDAQ:DRRX
59.3m USD
-111%
US
Eli Lilly and Co
NYSE:LLY
1T USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
492.8B USD
27%
CH
Roche Holding AG
SIX:ROG
262.7B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
217.7B GBP
16%
CH
Novartis AG
SIX:NOVN
214B CHF
26%
US
Merck & Co Inc
NYSE:MRK
270.8B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
33%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
-126%
US
Pfizer Inc
NYSE:PFE
144.6B USD
16%
No Stocks Found

DURECT Corp
Glance View

Market Cap
59.3m USD
Industry
Pharmaceuticals

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 79 full-time employees. The company went IPO on 2000-09-28. The firm's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The firm is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with severe alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The firm focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug.

DRRX Intrinsic Value
12.09 USD
Undervaluation 84%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-111.5%
=
Net Income
-3.5m
/
Revenue
3.1m
What is the Net Margin of DURECT Corp?

Based on DURECT Corp's most recent financial statements, the company has Net Margin of -111.5%.

Back to Top